Clinical features and treatment efficacy of peginterferon alfa plus ribavirin in chronic hepatitis C patients coinfected with hepatitis B virus.

Yu Jin Kim, Jin Woo Lee, Yun Soo Kim, Sook Hyang Jeong, Young Seok Kim, Hyung Joon Yim, Bo Hyun Kim, Chun Kyon Lee, Choong Kee Park, Sang Hoon Park

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Cross-sectional studies have documented that 2-10% of patients who are chronically infected with hepatitis C virus (HCV) are also positive for hepatitis B virus (HBV) surface antigen (HBsAg). Data related to HCV-HBV coinfection are lacking in Korea. This study evaluated the clinical characteristics, the treatment efficacy of peginterferon alfa plus ribavirin, and the changes induced by such treatment in HBV status in chronic hepatitis C (CHC) patients coinfected with HBV. Eighteen (2.37%) HBsAg-positive CHC patients were selected from among the 758 subjects from the K(G)yeonggi-Incheon Peginterferon alfa and ribavirin in chronic hepatitis C Treatment (KIPECT) study, which evaluated the treatment efficacy and safety of peginterferon alfa plus ribavirin in CHC patients. Data on changes in the status of HBV infections were obtained. HCV genotype 1b was the most common (44%). The overall sustained virologic response rate was 72% in all patients, and 60% and 87.5% in genotypes 1 and 2, respectively. Two of the 18 patients were positive for HBeAg, and 15 had baseline HBV DNA level of less than 2,000 IU/mL. Two of the three whose levels exceeded this threshold showed no detectable DNA after treatment. After the completion of treatment, serum HBV DNA levels were increased in the two patients whose baseline HBV DNA levels were less than 2,000 IU/mL. The prevalence of HBV coinfection in CHC patients was 2.37% and most of the patients were inactive carriers. The treatment efficacy was similar to that of HCV mono-infection. Reactivation of HBV replication was observed in some patients after CHC treatment.

Original languageEnglish
Pages (from-to)199-205
Number of pages7
JournalThe Korean journal of hepatology
Volume17
Issue number3
Publication statusPublished - 2011 Sep 1
Externally publishedYes

Fingerprint

Ribavirin
Chronic Hepatitis C
Hepatitis B virus
Hepacivirus
DNA
Virus Diseases
Coinfection
Genotype
Therapeutics
Hepatitis B e Antigens
Surface Antigens
Korea
Hepatitis B Surface Antigens
Virus Replication
Cross-Sectional Studies
Safety

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Clinical features and treatment efficacy of peginterferon alfa plus ribavirin in chronic hepatitis C patients coinfected with hepatitis B virus. / Kim, Yu Jin; Lee, Jin Woo; Kim, Yun Soo; Jeong, Sook Hyang; Kim, Young Seok; Yim, Hyung Joon; Kim, Bo Hyun; Lee, Chun Kyon; Park, Choong Kee; Park, Sang Hoon.

In: The Korean journal of hepatology, Vol. 17, No. 3, 01.09.2011, p. 199-205.

Research output: Contribution to journalArticle

Kim, YJ, Lee, JW, Kim, YS, Jeong, SH, Kim, YS, Yim, HJ, Kim, BH, Lee, CK, Park, CK & Park, SH 2011, 'Clinical features and treatment efficacy of peginterferon alfa plus ribavirin in chronic hepatitis C patients coinfected with hepatitis B virus.', The Korean journal of hepatology, vol. 17, no. 3, pp. 199-205.
Kim, Yu Jin ; Lee, Jin Woo ; Kim, Yun Soo ; Jeong, Sook Hyang ; Kim, Young Seok ; Yim, Hyung Joon ; Kim, Bo Hyun ; Lee, Chun Kyon ; Park, Choong Kee ; Park, Sang Hoon. / Clinical features and treatment efficacy of peginterferon alfa plus ribavirin in chronic hepatitis C patients coinfected with hepatitis B virus. In: The Korean journal of hepatology. 2011 ; Vol. 17, No. 3. pp. 199-205.
@article{8010ff30a3df4b13b3fd5d33c47ee830,
title = "Clinical features and treatment efficacy of peginterferon alfa plus ribavirin in chronic hepatitis C patients coinfected with hepatitis B virus.",
abstract = "Cross-sectional studies have documented that 2-10{\%} of patients who are chronically infected with hepatitis C virus (HCV) are also positive for hepatitis B virus (HBV) surface antigen (HBsAg). Data related to HCV-HBV coinfection are lacking in Korea. This study evaluated the clinical characteristics, the treatment efficacy of peginterferon alfa plus ribavirin, and the changes induced by such treatment in HBV status in chronic hepatitis C (CHC) patients coinfected with HBV. Eighteen (2.37{\%}) HBsAg-positive CHC patients were selected from among the 758 subjects from the K(G)yeonggi-Incheon Peginterferon alfa and ribavirin in chronic hepatitis C Treatment (KIPECT) study, which evaluated the treatment efficacy and safety of peginterferon alfa plus ribavirin in CHC patients. Data on changes in the status of HBV infections were obtained. HCV genotype 1b was the most common (44{\%}). The overall sustained virologic response rate was 72{\%} in all patients, and 60{\%} and 87.5{\%} in genotypes 1 and 2, respectively. Two of the 18 patients were positive for HBeAg, and 15 had baseline HBV DNA level of less than 2,000 IU/mL. Two of the three whose levels exceeded this threshold showed no detectable DNA after treatment. After the completion of treatment, serum HBV DNA levels were increased in the two patients whose baseline HBV DNA levels were less than 2,000 IU/mL. The prevalence of HBV coinfection in CHC patients was 2.37{\%} and most of the patients were inactive carriers. The treatment efficacy was similar to that of HCV mono-infection. Reactivation of HBV replication was observed in some patients after CHC treatment.",
author = "Kim, {Yu Jin} and Lee, {Jin Woo} and Kim, {Yun Soo} and Jeong, {Sook Hyang} and Kim, {Young Seok} and Yim, {Hyung Joon} and Kim, {Bo Hyun} and Lee, {Chun Kyon} and Park, {Choong Kee} and Park, {Sang Hoon}",
year = "2011",
month = "9",
day = "1",
language = "English",
volume = "17",
pages = "199--205",
journal = "Clinical and molecular hepatology",
issn = "2287-2728",
publisher = "Korean Association for the Study of the Liver",
number = "3",

}

TY - JOUR

T1 - Clinical features and treatment efficacy of peginterferon alfa plus ribavirin in chronic hepatitis C patients coinfected with hepatitis B virus.

AU - Kim, Yu Jin

AU - Lee, Jin Woo

AU - Kim, Yun Soo

AU - Jeong, Sook Hyang

AU - Kim, Young Seok

AU - Yim, Hyung Joon

AU - Kim, Bo Hyun

AU - Lee, Chun Kyon

AU - Park, Choong Kee

AU - Park, Sang Hoon

PY - 2011/9/1

Y1 - 2011/9/1

N2 - Cross-sectional studies have documented that 2-10% of patients who are chronically infected with hepatitis C virus (HCV) are also positive for hepatitis B virus (HBV) surface antigen (HBsAg). Data related to HCV-HBV coinfection are lacking in Korea. This study evaluated the clinical characteristics, the treatment efficacy of peginterferon alfa plus ribavirin, and the changes induced by such treatment in HBV status in chronic hepatitis C (CHC) patients coinfected with HBV. Eighteen (2.37%) HBsAg-positive CHC patients were selected from among the 758 subjects from the K(G)yeonggi-Incheon Peginterferon alfa and ribavirin in chronic hepatitis C Treatment (KIPECT) study, which evaluated the treatment efficacy and safety of peginterferon alfa plus ribavirin in CHC patients. Data on changes in the status of HBV infections were obtained. HCV genotype 1b was the most common (44%). The overall sustained virologic response rate was 72% in all patients, and 60% and 87.5% in genotypes 1 and 2, respectively. Two of the 18 patients were positive for HBeAg, and 15 had baseline HBV DNA level of less than 2,000 IU/mL. Two of the three whose levels exceeded this threshold showed no detectable DNA after treatment. After the completion of treatment, serum HBV DNA levels were increased in the two patients whose baseline HBV DNA levels were less than 2,000 IU/mL. The prevalence of HBV coinfection in CHC patients was 2.37% and most of the patients were inactive carriers. The treatment efficacy was similar to that of HCV mono-infection. Reactivation of HBV replication was observed in some patients after CHC treatment.

AB - Cross-sectional studies have documented that 2-10% of patients who are chronically infected with hepatitis C virus (HCV) are also positive for hepatitis B virus (HBV) surface antigen (HBsAg). Data related to HCV-HBV coinfection are lacking in Korea. This study evaluated the clinical characteristics, the treatment efficacy of peginterferon alfa plus ribavirin, and the changes induced by such treatment in HBV status in chronic hepatitis C (CHC) patients coinfected with HBV. Eighteen (2.37%) HBsAg-positive CHC patients were selected from among the 758 subjects from the K(G)yeonggi-Incheon Peginterferon alfa and ribavirin in chronic hepatitis C Treatment (KIPECT) study, which evaluated the treatment efficacy and safety of peginterferon alfa plus ribavirin in CHC patients. Data on changes in the status of HBV infections were obtained. HCV genotype 1b was the most common (44%). The overall sustained virologic response rate was 72% in all patients, and 60% and 87.5% in genotypes 1 and 2, respectively. Two of the 18 patients were positive for HBeAg, and 15 had baseline HBV DNA level of less than 2,000 IU/mL. Two of the three whose levels exceeded this threshold showed no detectable DNA after treatment. After the completion of treatment, serum HBV DNA levels were increased in the two patients whose baseline HBV DNA levels were less than 2,000 IU/mL. The prevalence of HBV coinfection in CHC patients was 2.37% and most of the patients were inactive carriers. The treatment efficacy was similar to that of HCV mono-infection. Reactivation of HBV replication was observed in some patients after CHC treatment.

UR - http://www.scopus.com/inward/record.url?scp=84872097828&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872097828&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 199

EP - 205

JO - Clinical and molecular hepatology

JF - Clinical and molecular hepatology

SN - 2287-2728

IS - 3

ER -